Changes in the CEA gene are a basis for the lack of hepatic metastases in a spontaneous colorectal cancer primate model

2001 ◽  
Vol 120 (5) ◽  
pp. A167-A167
Author(s):  
R ZIMMER ◽  
P THOMAS ◽  
N CLAPP ◽  
C STANNERS ◽  
M TOBI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatic Metastases ◽  
Primate Model ◽  
Cea Gene

Changes in the CEA gene are a basis for the lack of hepatic metastases in a spontaneous colorectal cancer primate model

2001 ◽  
Vol 120 (5) ◽  
pp. A167
Author(s):  
Regis Zimmer ◽  
Peter Thomas ◽  
Neal K. Clapp ◽  
Clifford P. Stanners ◽  
Martin Tobi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatic Metastases ◽  
Primate Model ◽  
Cea Gene

Radiofrequency Ablation of Hepatic Metastases from Colorectal Cancer: Are Newer Generation Probes Better?

2006 ◽  
Vol 72 (10) ◽  
pp. 875-879 ◽  
Author(s):  
Aziz Ahmad ◽  
Steven L. Chen ◽  
Maihgan A. Kavanagh ◽  
David P. Allegra ◽  
Anton J. Bilchik
Keyword(s):  
Colorectal Cancer ◽  
Radiofrequency Ablation ◽  
First Generation ◽  
Hepatic Metastases ◽  
Disease Free Survival ◽  
Cancer Center ◽  
Free Survival ◽  
Alive With Disease ◽  
Disease Free

Second-generation radiofrequency ablation (RFA) probes and their successors have more power, shorter ablation times, and an increased area of ablation compared with the first-generation probes used before 2000. We examined whether the use of the newer probes has improved the clinical outcome of RFA for hepatic metastases of colorectal cancer at our tertiary cancer center. Of 160 patients who underwent RFA between 1997 and 2003, 52 had metastases confined to the liver: 21 patients underwent 46 ablations with the first-generation probes and 31 patients underwent 58 ablations with the newer probes. The two groups had similar demographic characteristics. At a median follow-up of 26.2 months, patients treated with the newer probes had a longer median disease-free survival (16 months vs 8 months, P < 0.01) and a lower rate of margin recurrence (5.2% vs 17.4%); eight patients had no evidence of disease and one patient was alive with disease. By contrast, of the 46 patients treated with the first-generation probes, 2 patients had no evidence of disease and 1 patient was alive with disease. Newer-generation probes are associated with lower rates of margin recurrence and higher rates of disease-free survival after RFA of hepatic metastases from colorectal cancer.

scholarly journals Studies on Hepatic Recurrence in Patients with Colorectal Cancer with Resected Hepatic Metastases

2001 ◽  
Vol 26 (6) ◽  
pp. 1415-1419
Author(s):  
Kaname ISHII ◽  
Gen-ichi NISHIMURA ◽  
Itasu NINOMIYA ◽  
Hirohisa KITAGAWA ◽  
Takashi FUJIMURA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatic Metastases ◽  
Hepatic Recurrence

scholarly journals Bevacizumab in neoadjuvant treatment of patients with liver metastases from colorectal carcinoma

2010 ◽  
Vol 18 (3) ◽  
pp. 75-78
Author(s):  
Ivan Nikolic ◽  
Svetlana Pavin ◽  
Biljana Kukic ◽  
Bogdan Bogdanovic ◽  
Miroslav Ilic ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Neoadjuvant Treatment ◽  
Hepatic Metastases ◽  
Response Rates ◽  
Control Group ◽  
Significant Difference ◽  
Experimental Group ◽  
Selection Of Patients ◽  
Selection Of

Background: Liver metastases are the leading cause of death in patients with colorectal cancer. Despite advances in chemotherapy, surgical resection of hepatic metastases is still considered the only curative options. However, the majority of patients have inoperable disease at presentation. Perioperative chemotherapy is the most successful way for improved selection of patients for resection. The aim of the study was to demonstrate if and to what extent does bevacizumab, introduced in chemotherapy, increase response rates, and development of liver metastases. Methods: Our study included 50 patients who were divided in two groups. The experimental group included patients who were treated with bevacizumab plus chemotherapy, and the control group included patients who were treated with chemotherapy only. Results: The comparison showed that the patients who were treated with bevacizumab became candidates for resection of liver metastases in higher percentage (85%:52%). In addition, distribution of patients regarding the development of metastases resulted in statistically significant difference. Ratio between the patients with good response from the experimental and the control group was 67%:39%. Ratio of patients with stable disease was 26%:48%, and of patients with progressive disease, it was 7%:3%. The estimate of margin after resection was statistically insignificant. Conclusion: Bevacizumab in combination with chemotherapy in therapy of liver metastases from primary colorectal cancer improves and increases response rates and development of liver metastases.

Sign in / Sign up

Export Citation Format

Share Document